Vericel (VCEL) Capital Expenditures (QoQ) (2010 - 2026)
Powered by 
Analysis
Vericel (VCEL) Capital Expenditures (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Vericel | 2.05 Bn | 1.89 Bn | 56.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.28% |
| Mar 31, 2026 | -33.20% |
| Dec 31, 2025 | -16.84% |
| Sep 30, 2025 | -67.66% |
| Jun 30, 2025 | -42.77% |
| Mar 31, 2025 | 3.08% |
| Dec 31, 2024 | -28.97% |
| Sep 30, 2024 | 15.80% |
| Jun 30, 2024 | 19.58% |
| Mar 31, 2024 | 78.90% |
| Dec 31, 2023 | 19.27% |
| Sep 30, 2023 | 97.45% |
| Jun 30, 2023 | 45.79% |
| Mar 31, 2023 | 68.66% |
| Dec 31, 2022 | -3.97% |
| Sep 30, 2022 | -28.87% |
| Jun 30, 2022 | -35.70% |
| Mar 31, 2022 | 210.90% |
| Dec 31, 2021 | -59.76% |
| Sep 30, 2021 | 16.29% |